MiR-342 suppression of an E2F signaling network limits metastatic outgrowth of triple negative breast cancer
RNA-seq (gene expression) · human · 15 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Breast cancerThis series is part of our curated briefing on it.
- Samples
- 15 samples: 6 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE307965_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1327896 and SRA study SRP619046. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 15 samples.
How we read this: 6 replicated groups read from 15 sample titles; they account for 15 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9229880 AGO HITS-CLIP of MDA-MB-231HM cells with miR-342-3p rep 1 AGO HITS-CLIP of MDA-MB…
- GSM9229881 AGO HITS-CLIP of MDA-MB-231HM cells with miR-342-3p rep 2 AGO HITS-CLIP of MDA-MB…
- GSM9229882 AGO HITS-CLIP of MDA-MB-231HM cells with miR-342-3p rep 3 AGO HITS-CLIP of MDA-MB…
- GSM9229883 AGO HITS-CLIP of MDA-MB-231HM cells with miR-342-5p rep 1 AGO HITS-CLIP of MDA-MB…
- GSM9229884 AGO HITS-CLIP of MDA-MB-231HM cells with miR-342-5p rep 2 AGO HITS-CLIP of MDA-MB…
- GSM9229885 AGO HITS-CLIP of MDA-MB-231HM cells with miR-342-5p rep 3 AGO HITS-CLIP of MDA-MB…
- GSM9229886 AGO HITS-CLIP of MDA-MB-231HM cells with neg miR rep 1 AGO HITS-CLIP of MDA-MB…
- GSM9229887 AGO HITS-CLIP of MDA-MB-231HM cells with neg miR rep 2 AGO HITS-CLIP of MDA-MB…
- GSM9229888 AGO HITS-CLIP of MDA-MB-231HM cells with neg miR rep 3 AGO HITS-CLIP of MDA-MB…
- GSM9234668 MDA-MB-231HM cells with miR-342-3p rep 1 MDA-MB-231HM cells with…
- GSM9234669 MDA-MB-231HM cells with miR-342-3p rep 2 MDA-MB-231HM cells with…
- GSM9234670 MDA-MB-231HM cells with miR-342-5p rep 1 MDA-MB-231HM cells with…
- GSM9234671 MDA-MB-231HM cells with miR-342-5p rep 2 MDA-MB-231HM cells with…
- GSM9234672 MDA-MB-231HM cells with negative control rep 1 MDA-MB-231HM cells with…
- GSM9234673 MDA-MB-231HM cells with negative control rep 2 MDA-MB-231HM cells with…
- GSE11121 The humoral immune system has a key prognostic impact in node-negative breast cancer 200 samples same disease briefing · shares negative
- GSE10885 An integromic analysis reveals that metaplastic carcinomas are distinct from basal-like tumors. 244 samples same disease briefing
- GSE10886 A Supervised Risk Predictor of Breast Cancer Based on Biological Subtypes 226 samples same disease briefing
- GSE104193 Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signalling and malignant features in vitro and in vivo 32 samples same disease briefing
- GSE104675 Role for the Transcriptional Activator ZRF1 in Breast Cancer Progression and Endocrine Resistance 6 samples same disease briefing
- GSE334033 A Patient-Derived Xenograft Model Identifies AK1 as a Key Regulator of Metastatic Potential in Primary Triple-Negative Breast Cancer 105 samples shares metastatic, negative
- GSE271120 TRAIL-induced cytokine production via NFKB2 pathway promotes neutrophil chemotaxis and immune suppression in triple negative breast cancers [MDA-MB-231] 17 samples shares suppression, negative
- GSE292004 OCT-2 is associated with pro-metastatic epigenomic properties of triple-negative breast cancer cells 12 samples shares metastatic, negative
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.